CLAREMONT, CA (PRWEB) MARCH 13, 2017
Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy.
Each year, the 43North business competition awards $5 million in cash prizes and services to some of the best and brightest entrepreneurs and startups from around the globe. Awards include a one $1 million grand prize, six $500,000 prizes and four $250,000 prizes.
43North is part of New York Governor Andrew Cuomo’s Buffalo Billion initiative, which is driving new economic opportunities...
Meet the students who will compete in Washington D.C., and find out why their inventions stand out among this year’s most inspiring entries. Next stop: Collegiate Inventors Competition Expo and Awards Ceremony in Alexandria, VA on November 4th, 2016.